Immunogenicity, safety and tolerance of a purified duck embryo vaccine (PDEV, VAXIRAB) for rabies post-exposure prophylaxis: Results of a multicentric study in India

Human Vaccines

Volumn 6, Issue 9, 2010, Pages 721-724

  Mahendra, Bangalore Jayakrishna ^a   Madhusudana, Shampur Narayan ^b   Sampath, Gadey ^c   Datta, Soma Subhra ^d   Ashwathnarayana, Doddabele Hanumanthaiah ^e   Venkatesh, Gonibeedu Manjunath ^e   Sudarshan, Mysore Kalappa ^e   Bilugumba, Gangaboraiah ^e   Shamanna, Manjula ^f  

^a Mandya Rajiv Gandhi University of Medical Sciences   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^c Institute of Preventive Medicine   (India)

^d Pasteur Institute   (India)

^e KEMPEGOWDA INSTITUTE OF MEDICAL SCIENCES   (India)

^f Zydus Cadila Health Care Ltd   (India)

Author keywords

Post exposure therapy; Purified duck embryo vaccine; Rabies; Vaccines

Indexed keywords

NEUTRALIZING ANTIBODY; RABIES IMMUNOGLOBULIN; RABIES VACCINE; UNCLASSIFIED DRUG; VAXIRAB;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOG BITE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INDIA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; PRESCHOOL CHILD; RABIES; SCHOOL CHILD; SEROCONVERSION; WORLD HEALTH ORGANIZATION;

EID: 78649376083     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.9.12216     Document Type: Article

References (15)

1. World Health Organization. World survey of rabies No 35 for the year 1999. WHO/CDS/CSR/EPH/2002.10. Geneva.
2. Sudarshan MK, Madhusudana SN, Mahendra BJ, Rao NS, Ashwathnarayana DH, Abdul Rahman S, et al. Assessing burden of human rabies in India: Results of a national multi-center epidemiological survey. Int J Infect Dis 2007; 11:29-35.
3. World Health Organization. Expert consultation on rabies. WHO Tech Rep Ser 931 Geneva WHO, 2005.
4. Gluck R, Matthieu JM, Wegman A, Mean F. Absence of myelin basic protein in an improved purified duck embryo vaccine. Neurochem Pathol 1986; 4:69-75.
5. Wegmann A, Gluck R, Keller H, Matthieu JM. A highly efficient, highly purified duck embryo rabies vaccine. Schweiz Med Wochenchr 1985; 115:1779-81.
6. Kamoltham T, Singhsa J, Promsaranee U, Sonthon P, Mathean P, Thinyounyong W. Elimination of human rabies in a canine endemic province in Thailand: Five year Programme. Bull World Health Organ 2003; 81:375-7.
7. Wild H, Tipkong P, Khawplod P. Economic issues in post exposure rabies Treatment J Travel Med 1999; 6:238-42.
8. Mahendra BJ, Madhusudana SN, Ashwathnarayana DH, Sampath G, Datta S, Sudarshan MK, et al. A comparative study on the immunogenecity, safety and tolerance of purified duck embryo vaccine (PDEV) manufactured in India (Vaxirab) and Switzerland (Lyssavac N): A randomized simulated post exposure study in healthy volunteers. Vaccine 2007; 25:8405-9.
9. th report. Tech Rep Ser 824 Geneva, WHO 1992.
10. nd Ed. Boca Raton, CRC Press 1991; 571-95.
11. Sudarshan MK, Mahendra BJ, Madhusudana SN, Ashwathnarayana DH, Sanjay TV, Gangaboraiah B, et al. Hum Vaccin 2005; 1:187-90.
12. Sehgal S, Bhattcharya D, Bharadwaj M. Ten year longitudinal study of the efficacy and safety of purified chick embryo vaccine for pre and post exposure of rabies in Indian population. J Commun Dis 1995; 27:1536-43.
13. Sehgal S, Bhattacharya D, Bharadwaj M. Clinical evaluation of purified vero cell rabies vaccine (PVRV) in patients bitten by rabid animals in India. J Commun Dis 1994; 26:139-46.
14. Sampath G, Reddy SV, Rao MLP, Rao YU, Palaniappan C. An immunogenicity study of a newly introduced purified vero cell rabies vaccine (Abhayrab) manufactured in in India. Vaccine 2005; 23:897-900.
15. th ed. Geneva, WHO 1996; 181-2.